What percentage of patients are affected by CINV when undergoing highly emetogenic chemotherapy (HEC)?

When considering the impact of highly emetogenic chemotherapy (HEC) on patients, research indicates that a significant majority experience chemotherapy-induced nausea and vomiting (CINV). The correct response represents this reality, as approximately 90% of patients undergoing HEC are at risk for CINV. This high percentage reflects the potent emetogenic potential of certain chemotherapy agents classified as highly emetogenic.

HEC is characterized by its ability to provoke substantial nausea and vomiting reactions during the treatment cycle, often necessitating preemptive measures such as antiemetic therapies to mitigate these side effects. Understanding the high incidence of CINV in patients receiving HEC underscores the importance of effective symptom management and the role of supportive care in improving overall patient outcomes.

Recognition of this statistic is crucial for healthcare providers to ensure they are prepared to offer appropriate interventions and support to patients undergoing therapies with a high likelihood of inducing CINV.